Treatment Advances in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Vooruitgang in de behandeling van lokaal gevorderd en gemetastaseerd niet-kleincellig longcarcinoom
Lung cancer is the leading cause of cancer mortality in the United States and Europe. Approximately 85% of the patients with lung cancer have non–small cell lung cancer (NSCLC), which can be classified into squamous, adeno, large cell and not otherwise specified (NOS) histologies. The most common histologies are: adenocarcinoma ( 50%), squamous cell ( 20%), and large cell ( 10%). More than two third of the patients have locally advanced or metastatic disease at the time of diagnosis.
|H.C. Hoogsteden (Henk)|
|Erasmus University Rotterdam|
|Merck NV/SA Belgium, GSK, Mundipharma, MSD, Pierre Fabre Médicament Bénélux, Boehringer-Ingelheim|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Surmont, V.M.F. (2010, January 7). Treatment Advances in Locally Advanced and Metastatic Non-Small Cell Lung Cancer. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/17725